IRD Stock Price Today (October 2026) — Opus Genetics, Inc. Analysis & Key Metrics 2026-10-20
Opus Genetics, Inc. (IRD) is trading at $4.01, up 4.97% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $13.47 (235.9% upside).
- Volatility is high (54.01% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-73.80% YoY) alongside competitive pressures in the Biotechnology space.
IRD Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Opus Genetics, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $281.01M
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+235.9% upside potential
Key Investor Questions About IRD
What investors need to know before buying
Based on current market data, IRD presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 36.34)
- Fundamentals say: Mixed signals (nuanced financial profile)
IRD's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for IRD investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $36.20M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, IRD stock traded between $1.70 and $7.07 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 54.01% annualized volatility and β=1.05, the stock exhibits moderate correlation to market moves—making IRD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
Opus Genetics Says FDA Approves Supplemental Application for Presbyopia Treatment
Opus Genetics to Present at the Chardan Annual Healthcare Conference
Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
Latest TickZen Insights
All insights →No TickZen article on IRD yet. Our newest analysis:
Explore More Analysis for IRD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 10, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Opus Genetics, Inc.
Opus Genetics, Inc. (IRD) is currently trading at $4.01. The RSI (14-day) is at 36.3, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $13.47 implies 235.9% upside from current levels. Volatility is high at 54.0% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Opus Genetics, Inc. (IRD): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Sales is 33.85. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 17 analysts covering IRD, the consensus price target is $13.47. This represents a 235.9% upside from the current price of $4.01. The range spans from a low target of $8.00 to a high target of $20.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Opus Genetics, Inc. (IRD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Opus Genetics, Inc. (IRD) investors include: 1. High volatility (54.0% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-73.8% YoY), indicating potential business headwinds. 4. Elevated short interest (16.4% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Opus Genetics, Inc.'s (IRD) current debt and financial health profile: Total debt stands at $36.20M. The current ratio is 12.19, indicating strong short-term liquidity. The quick ratio is 11.87. The company holds $88.81M in cash and equivalents. Free cash flow is negative at -$40.67M, which could limit the company's ability to manage debt obligations.